PT Kalbe Farma Tbk (PTKFF)
0.0524
0.00 (0.00%)
USD |
OTCM |
Aug 27, 16:00
PT Kalbe Farma Net Income (Quarterly) : 52.51M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 52.51M |
| March 31, 2026 | 62.45M |
| December 31, 2025 | 63.03M |
| September 30, 2025 | 40.75M |
| June 30, 2025 | 55.66M |
| March 31, 2025 | 67.93M |
| December 31, 2024 | 53.82M |
| September 30, 2024 | 35.83M |
| June 30, 2024 | 52.24M |
| March 31, 2024 | 63.09M |
| December 31, 2023 | 45.14M |
| September 30, 2023 | 36.58M |
| June 30, 2023 | 44.58M |
| March 31, 2023 | 56.11M |
| December 31, 2022 | 58.83M |
| September 30, 2022 | 57.69M |
| June 30, 2022 | 56.32M |
| March 31, 2022 | 59.44M |
| December 31, 2021 | 63.67M |
| September 30, 2021 | 56.53M |
| June 30, 2021 | 54.76M |
| March 31, 2021 | 51.13M |
| December 31, 2020 | 50.72M |
| September 30, 2020 | 45.25M |
| June 30, 2020 | 49.09M |
| Date | Value |
|---|---|
| March 31, 2020 | 47.49M |
| December 31, 2019 | 42.09M |
| September 30, 2019 | 47.26M |
| June 30, 2019 | 47.34M |
| March 31, 2019 | 42.71M |
| December 31, 2018 | 44.87M |
| September 30, 2018 | 41.10M |
| June 30, 2018 | 45.55M |
| March 31, 2018 | 44.03M |
| December 31, 2017 | 47.34M |
| September 30, 2017 | 43.09M |
| June 30, 2017 | 48.20M |
| March 31, 2017 | 44.68M |
| December 31, 2016 | 46.36M |
| September 30, 2016 | 42.94M |
| June 30, 2016 | 44.82M |
| March 31, 2016 | 42.62M |
| December 31, 2015 | 38.02M |
| September 30, 2015 | 32.47M |
| June 30, 2015 | 41.66M |
| March 31, 2015 | 41.96M |
| December 31, 2014 | 48.59M |
| September 30, 2014 | 43.14M |
| June 30, 2014 | 44.17M |
| March 31, 2014 | 42.75M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AstraZeneca PLC | 3.076B |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Avadel Pharmaceuticals Plc | 0.02M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 559.49M |
| Total Expenses (Quarterly) | 508.65M |
| EPS Diluted (Quarterly) | 0.0011 |
| Enterprise Value | 2.219B |
| Gross Profit Margin (Quarterly) | 35.90% |
| Profit Margin (Quarterly) | 9.39% |
| Earnings Yield | 8.97% |
| Operating Earnings Yield | 11.45% |
| Normalized Earnings Yield | 8.970 |